SPECT/CT using [99mTc]-labeled anti-programmed death-ligand 1 (PD-L1) single-domain antibody (NM-01) to predict response to immune checkpoint inhibition in non-small cell lung cancer: preliminary results from the PD-L1 Expression in Cancer (PECan) study.
Daniel Hughes, Gitasha Chand, Levente Meszaros, Kathryn Adamson, Jessica Johnson, Damion Bailey, Victoria Gibson, Scott Edmonds, Alexandros Georgiou, Eleni Karapanagiotou, Debra Josephs, Emma McLean, Hong Hoi Ting, James Spicer, Vicky Goh, Gary Cook
Research output: Contribution to journal › Meeting abstract › peer-review
Fingerprint
Dive into the research topics of 'SPECT/CT using [99mTc]-labeled anti-programmed death-ligand 1 (PD-L1) single-domain antibody (NM-01) to predict response to immune checkpoint inhibition in non-small cell lung cancer: preliminary results from the PD-L1 Expression in Cancer (PECan) study.'. Together they form a unique fingerprint.